ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Pre-Mkt 06-17 07:00:15 EDT

1.29

+0.03

+2.38%

High1.36	Low1.23	Vol431.24K
Open1.23	D1 Closing1.26	Amplitude10.71%
Mkt Cap33.54M	Tradable Cap27.31M	Total Shares26.00M
T/O574.72K	T/O Rate2.04%	Tradable Shares21.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":1.29,"timestamp":1781640000000,"preClose":1.26,"halted":0,"volume":431237,"delay":0,"changeRate":0.02380952380952383,"floatShares":21172300,"shares":26000400,"eps":-0.379546,"marketStatus":"Pre-Mkt","change":0.03,"latestTime":"06-17 07:00:15 EDT","open":1.23,"high":1.36,"low":1.225,"amount":574721.9264019,"amplitude":0.107143,"askPrice":1.35,"askSize":100,"bidPrice":1.09,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.379546,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781703000000},"marketStatusCode":1,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":1.29,"postHourTrading":{"tag":"盘后","latestPrice":1.32,"preClose":1.29,"latestTime":"18:07 EDT","volume":270,"amount":346.9,"timestamp":1781647675518,"change":0.03,"changeRate":0.023256,"amplitude":0.023256},"volumeRatio":5.599389728546466,"impliedVol":1.8394,"impliedVolPercentile":0.8458},"requestUrl":"/m/hq/s/ABVC","defaultTab":"news","newsList":[{"id":"2640435559","title":"Cingulate Faces FDA Delay But Maintains ADHD Drug Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2640435559","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640435559?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:32","pubTimestamp":1780403558,"startTime":"0","endTime":"0","summary":"Cingulate Inc ( ($CING) ) has shared an update. On June 2, 2026, Cingulate announced that the U.S. Food and Drug Administration issued a Complete R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cingulate-faces-fda-delay-but-maintains-adhd-drug-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cingulate-faces-fda-delay-but-maintains-adhd-drug-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","ADHD","LABU","CING","BK4585","BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910025","title":"Cingulate Receives Complete Response Letter from FDA for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910025","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910025?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401600,"startTime":"0","endTime":"0","summary":"No Clinical Safety or Efficacy Concerns Currently IdentifiedAgency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of Requested InformationCompany is Wel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305119/0/en/Cingulate-Receives-Complete-Response-Letter-from-FDA-for-CTx-1301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","BK4139","LU2237443382.USD","LU0149725797.USD","IE00BKVL7J92.USD","LU0882574139.USD","ABVC","LU0971096721.USD","LU2746668461.USD","LU2746668974.SGD","IE00BZ1G4Q59.USD","BK4585","LU2237443465.HKD","ADHD","IE00BHPRN162.USD","BK4588","BK4007","CMC","LU2237443978.SGD","LU0170899867.USD","IE00B1BXHZ80.USD","LU2237443622.USD","IE00BFXG1179.USD","LU1363072403.SGD","LABU","LU2237443895.HKD","LU0267386448.USD","BK4006","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636381833","title":"Collegium Pharma Leans on ADHD to Drive Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2636381833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636381833?lang=en_us&edition=fundamental","pubTime":"2026-05-20 13:15","pubTimestamp":1779254102,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical Inc. (($COLL)) has held its Q1 earnings call. Read on for the main highlights of the call. Collegium Pharmaceutical’s late...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/collegium-pharma-leans-on-adhd-to-drive-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/collegium-pharma-leans-on-adhd-to-drive-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ADHD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079367","title":"ABVC BioPharma Q1 EPS $(0.06), Same YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079367","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079367?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:26","pubTimestamp":1779110808,"startTime":"0","endTime":"0","summary":"ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52632789/abvc-biopharma-q1-eps-0-06-same-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636183020","title":"ABVC Biopharma Q1 FY26 net loss widens 79% to $1.69 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636183020","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636183020?lang=en_us&edition=fundamental","pubTime":"2026-05-18 19:23","pubTimestamp":1779103412,"startTime":"0","endTime":"0","summary":"ABVC Biopharma posted a net loss of $1.69 million for the three months ended March 31, 2026, widening 79% from a year earlier, while revenue was unchanged at no revenue.Operating loss widened to $1.57 million as operating expenses more than doubled to $1.57 million on higher stock-based compensation.Net interest expense narrowed to $45,612, down 78%, reflecting lower interest expense tied to converted notes.Working capital deficit widened to $4.74 million, while net cash used in operating activities increased 66% to $894,243.Management highlighted full repayment of the Lind Notes, ongoing efforts to collect licensing and collaboration amounts due, and plans to seek additional financing while managing expenses amid going-concern uncertainty.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL8bptrp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635584660","title":"ABVC BioPharma delays filing quarterly report for period ended March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635584660","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635584660?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:04","pubTimestamp":1778879076,"startTime":"0","endTime":"0","summary":"ABVC BioPharma filed a Form 12b-25 late notice for its quarterly report for period ended March 31, 2026.Form 10-Q missed deadline as management was unable to finalize report and XBRL exhibit without unreasonable effort or expense.Filing targeted within SEC extension window of five calendar days following prescribed due date.Notice indicated no expected significant change in results of operations versus corresponding prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible f","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLnMYsZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635125427","title":"Press Release: Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2635125427","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635125427?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:00","pubTimestamp":1778760000,"startTime":"0","endTime":"0","summary":"KANSAS CITY, Kan., May 14, 2026  -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release  drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update.\"Cingulate remains focused on disciplined execution in 2026 and we believe we are well positioned to bring our lead ADHD asset, CTx-1301, to market,\" said Cingulate CEO Shane J. Schaffer. \"We continue to engage constructively with the FDA on our new drug application while advancing commercial readiness and manufacturing capabilities, and believe our current resources provide an extended cash runway into 2027.\". process validation batch preparation for CTx-1301, which will serve as","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","ADHD","03160","BK4139","BK4007","BK4099","BK4588","ABVC","CING","TM","BK4585","LABU","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021113","title":"Collegium Pharmaceutical Completes AZSTARYS ADHD Business Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021113","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634021113?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:33","pubTimestamp":1778589207,"startTime":"0","endTime":"0","summary":"Collegium Pharmaceutical ( ($COLL) ) has provided an update. On May 12, 2026, Collegium Pharmaceutical completed its previously announced $650 mill...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/collegium-pharmaceutical-completes-azstarys-adhd-business-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/collegium-pharmaceutical-completes-azstarys-adhd-business-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COLL","BK4139","ADHD","BK4007","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634928215","title":"Press Release: Collegium Completes Acquisition of AZSTARYS(R) from Corium Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2634928215","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634928215?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:31","pubTimestamp":1778585460,"startTime":"0","endTime":"0","summary":"-- Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio --. -- Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection Through 2037 --. -- Collegium Raises 2026 Financial Guidance to Reflect Expected Immediate Accretion from Acquisition --. -- 2026 Total Product Revenues, Net Expected in the Range of $865 to $895 Million and Adjusted EBITDA in the Range of $475 to $500 Million --. \"We are pleased to complete the acquisition of AZSTARYS, a highly strategic addition to our portfolio that strengthens our position in ADHD and further reinforces our long-standing commitment to improving patient care and delivering shareholder value,\" said Vikram Karnani, President and Chief Executive Officer. \"AZSTARYS is a complementary and differentiated therapy that expands the treatment options we can offer patients and prescribers, and we look forward to rapidly integrating it into our existing comm","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","COLL","LENZ","BK4232","BK4007","BK4135","ADHD","R","BK4139","CNS","ABVC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634470661","title":"Yukiguni Maitake Sees FY Net Y2.54B","url":"https://stock-news.laohu8.com/highlight/detail?id=2634470661","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634470661?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:30","pubTimestamp":1778481000,"startTime":"0","endTime":"0","summary":"Yukiguni Maitake Co. Ltd. also released the following forecasts:. This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149347","title":"Press Release: Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149347","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149347?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"-- Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year --. -- Generated JORNAY PM Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year --. -- On Track to Close Acquisition of AZSTARYS in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio --. -- Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year --. -- Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million --. -- Reaffirmed Full-Year 2026 Guidance for the Current Business --. -- Generated JORNAY PM net revenue of $38.9 million, up 36% year-over-year. -- JORNAY PM prescriptions reached an all-time high in the 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC","BK4007","COLL","BK4022","BK4232","R","PRGS","LU2065732104.USD","AG","BK4097","BK4210"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633154088","title":"Regencell Bioscience Holdings Faces Federal Securities Lawsuit Over Alleged Market Manipulation Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2633154088","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633154088?lang=en_us&edition=fundamental","pubTime":"2026-05-07 04:21","pubTimestamp":1778098896,"startTime":"0","endTime":"0","summary":"Regencell (RGC) promoted a traditional Chinese medicine approach to treating ADHD and autism. A small company with twelve employees, no approved or...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/regencell-bioscience-holdings-faces-federal-securities-lawsuit-over-alleged-market-manipulation-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/regencell-bioscience-holdings-faces-federal-securities-lawsuit-over-alleged-market-manipulation-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","US7Y.BOND","US10Y.BOND","TLT","BK4539","RGC","US30Y.BOND","BK4007","US3Y.BOND","TMF","US12M.BOND","US5Y.BOND","US6M.BOND","ABVC","US2Y.BOND","TLTW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632229953","title":"Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2632229953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632229953?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:31","pubTimestamp":1777897864,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (ANRO) announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 in patie...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-presents-phase-2a-data-for-alto-207-in-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-presents-phase-2a-data-for-alto-207-in-mdd-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALTO","BK4007","BK4138","ABVC","BK4109","BK4139","ANRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632998647","title":"Regencell Bioscience Holdings Faces Investor Lawsuit Alleging Securities Fraud Tied to DOJ Investigation and Stock Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2632998647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632998647?lang=en_us&edition=fundamental","pubTime":"2026-05-02 03:47","pubTimestamp":1777664866,"startTime":"0","endTime":"0","summary":"Regencell (RGC) described itself as an early-stage bioscience company developing traditional Chinese medicine (“TCM”) treatments for ADHD and autis...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/regencell-bioscience-holdings-faces-investor-lawsuit-alleging-securities-fraud-tied-to-doj-investigation-and-stock-volatility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/regencell-bioscience-holdings-faces-investor-lawsuit-alleging-securities-fraud-tied-to-doj-investigation-and-stock-volatility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","RGC","BK4139","BK4007","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631952919","title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631952919","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631952919?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:30","pubTimestamp":1777494600,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., April  29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3284304/0/en/Neuronetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC","STIM","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902208","title":"Humanwell Healthcare Subsidiary Gets China Nod for ADHD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902208","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626902208?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:37","pubTimestamp":1775723836,"startTime":"0","endTime":"0","summary":"China's drug regulator approved the dextromethorphan hydrochloride sustained-release capsules produced by Humanwell Healthcare  subsidiary Yichang Humanwell Pharmaceutical.The approval is for the indication of attention deficit hyperactivity disorder in children aged six years and older, according to a Thursday filing with the Shanghai bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK4139","BK0012","BK4588","BK4581","ADHD","BK0188","XBI","XLV","LABU","600079","BK0185","BK0028","LU0029874061.USD","BK4137","HCSG","BK0096","BK0070","BK4585","ABVC","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622967803","title":"ABVC BioPharma Shareholders Back Board, Equity Plan Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2622967803","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622967803?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:47","pubTimestamp":1774644430,"startTime":"0","endTime":"0","summary":"The latest update is out from ABVC BioPharma ( ($ABVC) ). On March 26, 2026, ABVC BioPharma held its 2026 annual shareholder meeting, where investo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abvc-biopharma-shareholders-back-board-equity-plan-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abvc-biopharma-shareholders-back-board-equity-plan-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4215","EQR","BK4585","ABVC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622870708","title":"ABVC Biopharma held annual shareholder meeting; quorum reached with 10.6 million shares represented by proxy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622870708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622870708?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:06","pubTimestamp":1774641992,"startTime":"0","endTime":"0","summary":"ABVC BioPharma held its annual shareholder meeting on March 26, 2026.Shareholders approved the re-election of 11 directors to the board.An increase to the Amended and Restated 2016 Equity Incentive Plan to set the aggregate share reserve at 15% of issued and outstanding common stock as of the meeting date was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL8VgnJw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622989619","title":"Press Release: LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989619","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989619?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"Reported positive results from potentially registrational Phase 2 trial of. Advanced LB-102 into late-stage development in multiple indications with initiation of. a pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trial. Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for the. adjunctive treatment of major depressive disorder  in early 2027. Cash, cash equivalents, and investments of $295.2 million as of December 31, 2025,and proceeds from recent $100 million private placement, expected to provide cash runway into Q2 2029. The Company is building a pipeline that leverages the broad therapeutic potential of LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.-- Reported positive results in January 2025 from a robust 359 patient Phase. 2 trial  of LB-102 in acute schizophrenia. The trial met the. baseline in the Positive and Negative Syndrome Scale  ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4233","LBRX","LB","ABVC","BK4213","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622885239","title":"BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2622885239","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622885239?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"BURLINGTON, Mass. and JERUSALEM, March  26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262880/17676/en/BrainsWay-Completes-Additional-6-Million-Milestone-Based-Investment-in-Neurolief-Ltd-Following-FDA-Approval-of-Proliv-Rx-System-for-MDD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4139","BK4585","ABVC","BK4149","FSS","LU0054578231.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":-0.0227},{"period":"1month","weight":0.1835},{"period":"3month","weight":0.0574},{"period":"6month","weight":-0.3676},{"period":"1year","weight":-0.3385},{"period":"ytd","weight":-0.3944}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.0151},{"period":"3month","weight":0.1344},{"period":"6month","weight":0.1092},{"period":"1year","weight":0.245},{"period":"ytd","weight":0.1003}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.072395},{"month":2,"riseRate":0.125,"avgChangeRate":-0.057705},{"month":3,"riseRate":0.625,"avgChangeRate":0.040736},{"month":4,"riseRate":0.375,"avgChangeRate":0.01167},{"month":5,"riseRate":0.5,"avgChangeRate":0.035623},{"month":6,"riseRate":0.25,"avgChangeRate":1.141383},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.097297},{"month":8,"riseRate":0.5,"avgChangeRate":-0.054488},{"month":9,"riseRate":0.375,"avgChangeRate":-0.065685},{"month":10,"riseRate":0.375,"avgChangeRate":-0.067045},{"month":11,"riseRate":0.625,"avgChangeRate":0.051458},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012195}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}